Download PDF
Dialyse aktuell 2019; 23(S 01): S4-S10
DOI: 10.1055/a-0986-7447
Schwerpunkt | Nephrologie
© Georg Thieme Verlag Stuttgart · New York

Therapie der renalen Anämie

Aktuell rekombinantes Epoetin – in Zukunft orale HIF-Stabilisatoren?
Thilo Krüger
1   DaVita Clinical Research Deutschland GmbH, Düsseldorf
2   MVZ DaVita Geilenkirchen GmbH, Geilenkirchen
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2019 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Die renale Anämie gehört zu den wesentlichen Begleiterkrankungen von Patienten mit fortgeschrittener Nierenerkrankung. Somit sind die Diagnose und Therapie eine wesentliche Aufgabe des Nephrologen. Seit Zulassung von Epoetin hat sich dieses Feld enorm verbreitert und ist deutlich komplexer geworden. Dieser Artikel beschreibt pathophysiologische Zusammenhänge sowie die aktuellen Empfehlungen zur Therapie mittels Epoetin. Orale Antagonisten der HIF-Ph (Hypoxia-Inducible-Factor Prolylhydroxylase), auch HIF-Stabilisatoren genannt, können eine weitere wesentliche Neuerung in der Therapie der renalen Anämie darstellen. Diese neue, noch in Erprobung befindliche Substanzklasse wird im vorliegenden Beitrag ebenfalls vorgestellt und es wird über die bisherigen Erkenntnisse berichtet.

 

  • Literatur

  • 1 WHO Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Genf (Schweiz): World Health Organization 2011 Im Internet http://www.who.int/vmnis/indicators/haemoglobin.pdf Stand: 13.11.2019
    PubMedGoogle Scholar
  • 2 McClellan W, Aronoff SL, Bolton WK. et al The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501-1510 doi:10.1185/030079904X2763
    CrossrefPubMedGoogle Scholar
  • 3 Kalantar-Zadeh K, Aronoff GR. Hemoglobin Variability in Anemia of Chronic Kidney Disease. J Am Soc Nephrol 2009; 20: 479-487 doi:10.1681/ASN.2007070728
    CrossrefPubMedGoogle Scholar
  • 4 Regidor DL, Kopple JD, Kovesdy CP. et al Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients. J Am Soc Nephrol 2006; 17: 1181-1191 doi:10.1681/ASN.2005090997
    CrossrefPubMedGoogle Scholar
  • 5 Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006; 69: 560-564 doi:10.1038/sj.ki.5000105
    CrossrefPubMedGoogle Scholar
  • 6 Eriksson D, Goldsmith D, Teitsson S. et al Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol 2016; 17: 97 doi:10.1186/s12882-016-0312-9
    CrossrefPubMedGoogle Scholar
  • 7 Lönnberg M, Garle M, Lönnberg L, Birgegård G. Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis. J Pharm Biomed Anal 2013; 81–82: 187-192 doi:10.1016/j.jpba.2013.04.009
    PubMedGoogle Scholar
  • 8 Souma T, Suzuki N, Yamamoto M. Renal erythropoietin-producing cells in health and disease. Front Physiol 2015; 6: 167 doi:10.3389/fphys.2015.0016
    PubMedGoogle Scholar
  • 9 Noguchi CT, Wang L, Rogers HM. et al Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 2008; 10: e36 doi:10.1017/S1462399408000860
    CrossrefPubMedGoogle Scholar
  • 10 Artunc F, Risler T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transplant 2007; 22: 2900-2908 doi:10.1093/ndt/gfm316
    CrossrefPubMedGoogle Scholar
  • 11 Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol 2006; 26: 261-268 doi:10.1016/j.semnephrol.2006.06.001
    CrossrefPubMedGoogle Scholar
  • 12 Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 2002; 17 (Suppl. 01) 48-52 doi:10.1093/ndt/17.suppl_1.48
    PubMedGoogle Scholar
  • 13 Bernhardt WM, Wiesener MS, Scigalla P. et al Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD. J Am Soc Nephrol 2010; 21: 2151-2156 doi:10.1681/ASN.2010010116
    CrossrefPubMedGoogle Scholar
  • 14 Macdougall IC, Obrador GT. How important is transfusion avoidance in 2013?. Nephrol Dial Transplant 2013; 28: 1092-1099 doi:10.1093/ndt/gfs575
    CrossrefPubMedGoogle Scholar
  • 15 U. S. Renal Data System USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda (MD, USA): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2003
    PubMedGoogle Scholar
  • 16 Singh AK, Szczech L, Tang KL. et al Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N Engl J Med 2006; 355: 2085-2098 doi:10.1056/NEJMoa065485
    CrossrefPubMedGoogle Scholar
  • 17 Drüeke TB, Locatelli F, Clyne N. et al Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med 2006; 355: 2071-2084 doi:10.1056/NEJMoa062276
    CrossrefPubMedGoogle Scholar
  • 18 Besarab A, Bolton WK, Browne JK. et al The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin. N Engl J Med 1998; 339: 584-590 doi:10.1056/NEJM199808273390903
    CrossrefPubMedGoogle Scholar
  • 19 Pfeffer MA, Burdmann EA, Chen CY. et al TREAT Investigators. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med 2009; 361: 2019-2032 doi:10.1056/NEJMoa0907845
    CrossrefPubMedGoogle Scholar
  • 20 Bellinghieri G, Condemi CG, Saitta S. et al Erythropoiesis-Stimulating Agents: Dose and Mortality Risk. J Ren Nutr 2015; 25: 164-168 doi:10.1053/j.jrn.2014.10.012
    CrossrefPubMedGoogle Scholar
  • 21 U. S. Renal Data System 2014 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Bethesda (MD, USA): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2014
    PubMedGoogle Scholar
  • 22 Collister D, Komenda P, Hiebert B. et al The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164: 472-478 doi:10.7326/M15-1839
    CrossrefPubMedGoogle Scholar
  • 23 Overgaard J, Hoff CM, Hansen HS. et al DAHANCA 10 – Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Radiother Oncol 2018; 127: 12-19 doi:10.1016/j.radonc.2018.02.018
    CrossrefPubMedGoogle Scholar
  • 24 Smith Jr RE, Aapro MS, Ludwig H. et al Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Oncol 2008; 26: 1040-1050 doi:10.1200/JCO.2007
    CrossrefPubMedGoogle Scholar
  • 25 Wright DG, Wright EC, Narva AS. et al Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. Clin J Am Soc Nephrol 2015; 10: 1822-1830 doi:10.2215/CJN.01590215
    CrossrefPubMedGoogle Scholar
  • 26 Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. J Am Soc Nephrol 2019; 30: 1037-1048 doi:10.1681/ASN.2018101007
    CrossrefPubMedGoogle Scholar
  • 27 Wiesener MS, Jürgensen JS, Rosenberger C. et al Widespread hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J 2003; 17: 271-273 doi:10.1096/fj.02-0445fje
    CrossrefPubMedGoogle Scholar
  • 28 Epstein ACR, Gleadle JM, McNeill LA. et al C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation. Cell 2001; 107: 43-54 doi:10.1016/s0092-8674(01)00507-4
    CrossrefPubMedGoogle Scholar
  • 29 Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47 doi:10.1038/nrc704
    CrossrefPubMedGoogle Scholar
  • 30 Hasegawa S, Tanaka T, Nangaku M. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease: Curr Opin Nephrol Hypertens. 2018; 27: 331-338 doi:10.1097/MNH.0000000000000431
    PubMedGoogle Scholar
  • 31 Flamme I, Oehme F, Ellinghaus P. et al Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85–3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects. PLoS One 2014; 9: e111838 doi:10.1371/journal.pone.0111838
    CrossrefPubMedGoogle Scholar
  • 32 Schwartz AJ, Das NK, Ramakrishnan SK. et al Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload. J Clin Invest 2018; 129: 336-348 doi:10.1172/JCI122359
    CrossrefPubMedGoogle Scholar
  • 33 U. S. Renal Data System USRDS 2009 Annual Data Report: atlas of end-stage renal disease in the United States. Bethesda (MD, USA): National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases. 2009
    PubMedGoogle Scholar
  • 34 Halstenson CE, Macres M, Katz SA. et al Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50: 702-712 doi:10.1038/clpt.1991.210
    CrossrefPubMedGoogle Scholar
  • 35 Macdougall IC, Gray SJ, Elston O. et al Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients. J Am Soc Nephrol 1999; 10: 2392-2395
    PubMedGoogle Scholar
  • 36 EMA Produktinformationen Aranesp. Im Internet https://www.ema.europa.eu/en/documents/product-information/aranesp-epar-product-information_en.pdf Stand: 13.11.2019
    Google Scholar
  • 37 EMA Produktinformationen Mircera. Im Internet https://www.ema.europa.eu/en/documents/product-information/mircera-epar-product-information_en.pdf Stand: 13.11.2019
    Google Scholar
  • 38 EMA Produktinformationen Epoetin alfa HEXAL. Im Internet https://www.ema.europa.eu/en/documents/product-information/epoetin-alfa-hexal-epar-product-information_en.pdf Stand: 13.11.2019
    Google Scholar
  • 39 Chapter 3: Use of ESAs and other agents treat anemia in CKD Kidney Int Suppl (2011). 2012; 2: 299-310 doi:10.1038/kisup.2012.35
    PubMedGoogle Scholar
  • 40 Clinical Trials. Im Internet: www.clinicaltrials.gov Stand: 13.11.2019